RxDoctor Payments Data

Hector Silva, MD

Medical Oncology · Coto Laurel, PRNPI 1134194533

Payments from drug & device makers

$10,474in general payments, 2019–2025

Across 47 payments — averaging $222.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$10K
  • Medtronic$273
  • Eli Lilly$142
  • PBG Puerto Rico LLC$115
  • Seagen Inc.$75
  • Johnson & Johnson$73
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$1,11781%
  • Education$26519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical oncology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$483,572
Medicare patients
29
Services billed
21,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide106$1,568,687
PomalystPomalidomide21$479,784
JakafiRuxolitinib Phosphate19$323,107
OjjaaraMomelotinib Dihydrochloride11$311,402
PromactaEltrombopag Olamine31$288,823
TukysaTucatinib11$287,567
VerzenioAbemaciclib18$278,412
KeytrudaPembrolizumab17$188,680
XtandiEnzalutamide13$187,692
CalquenceAcalabrutinib Maleate12$183,678
Lupron DepotLeuprolide Acetate52$104,488
VotrientPazopanib Hcl15$65,735
XgevaDenosumab11$34,680
RetacritEpoetin Alfa-Epbx15$30,618
FemaraLetrozole21$17,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Seagen Inc.Tukysa$75$287,56711 claims
Lilly USA, LLCVerzenio$3$278,41218 claims
MerckKeytruda$29$188,68017 claims
AmgenXgeva$20$34,68011 claims
Johnson & JohnsonXarelto$73$7,45913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Coto Laurel

Where these figures come from

Is this you, or does something look wrong? →